Plain-English translation of NCT06667453 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing a new medication called to see if it is safe and tolerable for people with myotonic dystrophy type 1 (a genetic muscle disease). Half of the 24 participants will receive the medication in increasing doses every 4 weeks over 12 weeks, while the other half will receive a placebo (a harmless salt solution) to compare how the treatment works.
Myotonic dystrophy type 1 causes progressive muscle weakness and stiffness, and there are limited treatment options available. This study is exploring whether this new medication could help manage symptoms and be a safe option for patients.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic once every 4 weeks for 12 weeks to receive either the new medication or a placebo as an injection. You will also undergo a small muscle biopsy (tissue sample collection) to help researchers understand how the medication affects your muscles. Throughout the study, you'll complete safety tests and assessments to help the research team monitor how well you tolerate the treatment.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
Canada
New Zealand